As ITUS Pivots to Cancer Diagnostics, Its Sub Continues Legacy Patent Assertion Against Cisco and Microsoft
In the summer of 2015, publicly traded NPE ITUS Corporation, announced executive changes and a new focus for the company’s future business: cancer diagnostics. This past November, ITUS continued its apparent pivot away from patent assertion, forming a new subsidiary to develop “immuno-therapy drugs against cancer”, revealing an initial focus on ovarian cancer, and indicating that the company will remain engaged in “limited patent licensing activities in the area of encrypted audio/video conference calling” only as part of its “legacy operations”, which would not “require material financial resources or attention of senior management”. Nevertheless, this past week, ITUS subsidiary Meetrix IP, LLC filed separate lawsuits against Cisco (1:18-cv-00309) and Microsoft (1:18-cv-00310), targeting the defendants’ WebEx and Skype (and Skype for Business) products, respectively, each with patents from its “encrypted audio/video conference calling” portfolio.
This content requires a subscription to view
- Over 7,000 news articles covering new patent cases, key policy decisions, and USPTO assignments
- Advanced custom alerts for campaigns and entities
- Proprietary litigation timelines
- Full access to Federal Circuit, PTAB, and ITC dockets
- Judge, venue, and law firm analytics